What about vaccinating people who have already had COVID? I get this question a lot. New answers now! 🧵
nytimes.com/2021/02/01/hea…
Excellent and rapid work to find that, for people who have previously had COVID, one COVID vaccine dose gives a bigger antibody response than seen in COVID-negative people receiving a normal two dose COVID vaccine regimen.
One study by Viviana Simon & @florian_krammer and colleagues. And an independent stduy by Sajadi and colleagues in Maryland.
One dose of vaccine gave high binding antibody titers
medrxiv.org/content/10.110…
And in the Sajadi study found high neutralizing antibodies.
medrxiv.org/content/10.110…
While they don't have the direct comparison group of COVID-negative people who received two vaccine doses, those neutralizing titers are convincingly high, and they track with the binding antibody
I have no problem with health officials who want to keep the vaccine schedule based on the Phase 3 trial data. But, to me, these data are convincing enough, in the context of current vaccines EUAs, that people with previously confirmed COVID-19, a single dose of vaccine is enough
, and with fewer side effects.
To be clear, in a non-pandemic situation, the data one would want to make such a recommendation would be quantitation of the following, in comparison to the regular COVID RNA vaccines schedule:
- side effects
- Neutralizing antibody titers
- T cell responses
- Durability of both antibodies and T cells
But, for me, the combo of high neutralizing/binding antibodies and the side effect reports are enough, even if it is a temporary recommendation for current pandemic conditions.
The question of WHEN a person with previously confirmed COVID should be immunized is a different question.
As previously mentioned, waiting 90 days is reasonable.
and the NEJM allows for a similar conclusion
Additional data could support different schedules in the future. But, while there is certainly evidence of immune memory and protective immunity against COVID lasting 6+ months (see our other work and tweets),
as I said on the BBC show The Evidence this past week, nothing compares to a Phase 3 clinical trial for proof! That is to say, the vaccines definitely protect, so the wisest course of action is to get vaccinated when you can.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Shane Crotty

Shane Crotty Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @profshanecrotty

2 Feb
SIX successful COVID-19 vaccines! SIX! Three just in the past week! Extraordinary. The newest one is the Russian (Rus) adenoviral (Ad) vector COVID vaccine. The clinical trial data look really good at face value. 🧵

doi.org/10.1016/S0140-…
92% efficacy overall, and 92% efficacy in people over 60 years old. Image
I will let clinical trial design experts weigh in on trial design features. I will comment on the basic outcomes and the immune responses.
Read 12 tweets
30 Jan
1/ Now for the thornier data.
2/ I covered the great news from the Novavax COVID vaccine UK Phase 3 trial.
3/ I covered the excellent news from the J&J COVID vaccine Phase 3 international trials.
Read 28 tweets
29 Jan
1/ J&J COVID-19 vaccine. Single dose Ad26 (adenoviral).

Another important COVID-19 vaccine success!

Topline J&J vaccine efficacy reported to be 100% against serious cases of COVID-19 more than 28 days after immunization. Those are big!
1/n

bit.ly/3tb7K5d
2/ That includes USA, Latin Amer, and South Africa study sites. It will be important to see more data, because the initial press release was definitely thin on data. But, initial report 72% efficacy against "moderate to severe" disease. That is good for a single dose immunization
3/ The J&J COVID-19 vaccine generated good immune responses in people after one immunization, but there was a substantial boost to the antibody response after a 2nd immunization. A 4x gain. (T cell responses after the 2nd dose were not reported)
nejm.org/doi/10.1056/NE…
Read 15 tweets
29 Jan
1/ Novavax UK first:
~90% protection again any symptomatic COVID-19. And that high level of protection was accomplished under conditions of very intense community transmission in the UK, which is a high bar. 1/n
bit.ly/3oEpann
2/ (i.e., most likely a higher bar for protection than USA summer transmission, or anywhere with low level SARS2 transmission). And that was under conditions of high prevalence of the "UK variant" (B117), which is significantly more transmissible than the parental SARS2 strain.
3/ The Novavax vaccine was quite protective against both the parental strain and the UK variant, which is welcome news.
Read 15 tweets
12 Jan
1/ Here's my review on adaptive immunity to COVID-19 and SARS-CoV-2. I hope you find it useful. It was a lot of work. Thanks to Prof Alex Sette @SetteLab and others for direct contributions and broader input over the year!
cell.com/cell/fulltext/… @CellCellPress Image
2/ And thanks to all of the amazing scientists and labs around the world that have done so much work making incredible progress on these challenging COVID-19 immunology topics in the past year!
3/ FYI, here's the right version of Figure 1. It should be updated in the next version posted online. Image
Read 5 tweets
9 Jan
1/ “I think this [study] is really important because there is a lot of fear and uncertainty at the moment about this specific question.”

“[the results are] not surprising, but it’s been really important to see some data.” 

washingtonpost.com/health/2021/01…
2/ Definitely good news to see these data on the Pfizer vaccine working against the 501 variant. If anything, the vaccine works better against this variant.
biorxiv.org/content/10.110…
3/ It isn't the end of the story, because the UK / SA variants have mutations in addition to 501, but these vaccine data are an important piece of the puzzle. As noted in the article, more is expected from labs in the coming weeks, but these results are expected & encouraging.
Read 4 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!